[bcl-2和nm23在上皮性卵巢癌中的表达及其临床意义]

[Expressions and their clinical significance of bcl-2 and nm23 in epithelial ovarian carcinoma].

作者信息

Cao L Q, Chen X M, Li X

机构信息

Department of Gynecology and Obstetrics, Xiangya Hospital, Hunan Medical University, Changsha 410008.

出版信息

Hunan Yi Ke Da Xue Xue Bao. 2000 Apr 28;25(2):188-90.

PMID:12212220

Abstract

The expressions of bcl-2 and nm23 protein in epithelial ovarian carcinoma were analyzed by immunohistochemical method. The results were that 1. the positive expression of bcl-2 protein was 60% (27/45) in epithelial carcinoma; the positive expression of bcl-2 protein in Grade I was 31.25% (5/16), in Grade II 57.14% (8/14), in Grade III 93.33% (14/15) and there were significant differences among them (P < 0.05); 2. the positive expression of nm23 protein was 40% (18/45) in epithelial carcinoma; the positive expression of bcl-2 protein in Stage I/II was 57.1% (12/21), in Stage III/IV 25% (6/24), and there was significant difference between them (P < 0.05). We conclude that the expressions of bcl-2 and nm23 protein are associated with tumor differentiation and clinical stage respectively. Analyzing the expressions of bcl-2 and nm23 are beneficial to the prognosis of the ovarian tumor patients.

摘要

采用免疫组织化学方法分析上皮性卵巢癌中bcl-2和nm23蛋白的表达情况。结果如下：1.上皮癌中bcl-2蛋白阳性表达率为60%（27/45）；Ⅰ级中bcl-2蛋白阳性表达率为31.25%（5/16），Ⅱ级为57.14%（8/14），Ⅲ级为93.33%（14/15），三者之间差异有统计学意义（P<0.05）；2.上皮癌中nm23蛋白阳性表达率为40%（18/45）；Ⅰ/Ⅱ期bcl-2蛋白阳性表达率为57.1%（12/21），Ⅲ/Ⅳ期为25%（6/24），两者之间差异有统计学意义（P<0.05）。我们得出结论，bcl-2和nm23蛋白的表达分别与肿瘤分化和临床分期相关。分析bcl-2和nm23的表达情况有利于卵巢肿瘤患者的预后判断。